JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Christophe Baufreton
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baufreton, C.
Right arrow Articles by de Brux, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baufreton, C.
Right arrow Articles by de Brux, J. L.
Related Collections
Right arrow Extracorporeal circulation
Right arrowRelated Article

J Thorac Cardiovasc Surg 2003;126:2116
© 2003 The American Association for Thoracic Surgery

Letter to the editor

Coagulation, fibrinolysis, and cell activation in patients and in shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface

Christophe Baufreton, MD, PhD, Jean Louis de Brux, MD

Department of Cardiac Surgery, University Hospital of Angers, Angers, France

The first 20% of the full text of this article appears below.

To the Editor:

Johnell and colleagues1 recently reported the improved biocompatibility of a new heparin-coated surface. They also presented results after modifications of the anticoagulation protocol. They concluded that a low dose of systemic heparin might not be sufficient to maintain the antithrombotic activity and that a high dose resulted in increased blood activation.

The design of the study merits discussion; otherwise, the conclusion might be misunderstood. In particular, the reduction of anticoagulation, even combined with a thromboresistant extracorporeal circuit, might appear detrimental for patients undergoing cardiopulmonary bypass (CPB). The basis for a safe low anticoagulation protocol in combination with . . . [Full Text of this Article]


Related Article

Reply to the Editor
Ray C.-J. Chiu
J. Thorac. Cardiovasc. Surg. 2003 126: 2117. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur J Cardiothorac Surg, June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.